NASDAQ: DBVTDbv Technologies Sa Stock
$0.58+0.01 (+1.75%)
Updated May 10, 2024
DBVT Price
$0.58
Fair Value Price
N/A
Market Cap
$111.09M
52 Week Low
$0.56
52 Week High
$2.37
P/E
-1.4x
P/B
0.99x
P/S
9.64x
PEG
N/A
Dividend Yield
N/A
Revenue
$14.94M
Earnings
-$79.51M
Gross Margin
100%
Operating Margin
-531.76%
Profit Margin
-532.1%
Debt to Equity
0.31
Operating Cash Flow
-$94M
Beta
0.55
Next Earnings
May 16, 2024
Ex-Dividend
N/A
Next Dividend
N/A
DBVT Overview
DBV Technologies S.A., a clinical-stage biopharmaceutical company, engages in the research and development of epicutaneous immunotherapy products. Its lead product candidate is Viaskin Peanut, an immunotherapy product, which has completed Phase III clinical trial for the treatment of peanut allergies in 4 to 11 years of age children, adolescents, and adults. The milk-induced company is also developing Viaskin Milk that is in Phase I/II clinical trial for the treatment of Immunoglobulin E (IgE) mediated cow's milk protein allergy (CMPA); Viaskin Egg, a pre-clinical stage product for the treatment of hen's egg allergy; and booster vaccine for Bordetella pertussis. Its other earlier stage research programs include a vaccine for the respiratory syncytial virus, as well as treatments for Crohn's disease, celiac disease, and type I diabetes. The company has a collaboration with Nestlé Health Science to develop MAG1C, a ready-to-use atopy patch test for the diagnosis of non-IgE mediated CMPA in infants and toddlers. DBV Technologies S.A. was incorporated in 2002 and is headquartered in Montrouge, France.
Zen Score
–
Industry Average (23)
You've viewed Zen Score for 10/10 free stocks. Upgrade to Premium to see how DBVT scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.
Due Diligence Checks
DBVT is unprofitable, so we are unable to calculate its intrinsic value according to an updated version of Benjamin Graham's Formula from "The Intelligent Investor"
Below Benjamin Graham Formula Value Valuation
DBVT is good value based on its book value relative to its share price (0.99x), compared to the US Biotechnology industry average (5.91x)
P/B vs Industry Valuation
DBVT is unprofitable, so we... subscribe to Premium to read more.
PEG Value Valuation
There are 30 more DBVT due diligence checks available for Premium users.
Be the first to know about important DBVT news, forecast changes, insider trades & much more!
DBVT News
Valuation
DBVT fair value
Fair Value of DBVT stock based on Discounted Cash Flow (DCF)
Price
$0.58
Fair Value
$2.27
Undervalued by
74.49%
DBVT is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
DBVT price to earnings (PE)
For valuing profitable companies with steady earnings
Company
-1.4x
Industry
6.42x
Market
30.02x
DBVT price to book (PB)
For valuing companies that are loss-making or have lots of physical asset
Company
0.99x
Industry
5.91x
DBVT is good value based... subscribe to Premium to read more.
P/B vs Industry Valuation
DBVT's financial health
Profit margin
Revenue
$1.4M
Net Income
-$27.3M
Profit Margin
-1,943.5%
DBVT's cash burn is expected... subscribe to Premium to read more.
Interest Coverage Financials
DBVT's profit margin has increased... subscribe to Premium to read more.
Profit Margin Growth Financials
Assets to liabilities
Assets
$145.9M
Liabilities
$34.2M
Debt to equity
0.31
DBVT's short-term assets ($119.56M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
DBVT's short-term assets ($119.56M) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
DBVT's debt has increased relative... subscribe to Premium to read more.
Shrinking Debt Financials
DBVT's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials
Cash flow
Operating
-$34.7M
Investing
-$2.1M
Financing
-$62.0k
DBVT's cash and short-term investments... subscribe to Premium to read more.
Debt Coverage Financials
DBVT vs Biotech Stocks
Dbv Technologies Sa Stock FAQ
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsHelp GuidesContactTwitterYouTubeNewsletterWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.